Drug news

NICE does not recommend Ninlaro (ixazomib) combination + lenalidomide + dexamethasone as a treatment for multiple myeloma.-Takeda

Read time: 1 mins

Last updated:27th Jun 2017

Published:28th Apr 2017

Source: Pharmawand

The National Institute for Health and Care Excellence (NICE), in a draft recommendation, has rejected Ninlaro (ixazomib) combination with lenalidomide and dexamethasone from Takeda as a cost effective treatment for Multiple Myeloma in patients who have had one or more treatments. NICE noted that the pivotal trial for the drug was still ongoing and available data are limited and it is unclear if the combination will prolong life. NICE considered that the progression free survival (PFS) benefits of the combination appear to reduce with longer follow up. Takeda responded that the TOURMALINE-MMI trial demonstrated that the combination increased PFS by around six months with less toxicity than competing therapies.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

FDA approves Alecensa (alectinib) as the first adjuvant treatment for people with ALK-positive early-stage lung cancer

Roche announced that the FDA has approved Alecensa (alectinib) for adjuvant treatment following tumour resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumours greater than 4 cm or node positive), as detected by an FDA-approved test

2 mins

Drug news

Iomab-B (apamistamab) to overcome high-risk TP53 mutation resulting in significant improvement in overall survival in patients with active relapsed refractory AML at the European Bone Marrow Transplant Annual Meeting

Actinium Pharmaceuticals, Inc. announced that results from the Phase III SIERRA trial of Iomab-B (apamistamab) were presented in an oral presentation at the 50th Annual European Bone Marrow Transplant Society Meeting (EBMT) held in Glasgow, Scotland on April 14-17

1 min

Drug news

FDA has granted a rolling New Drug Application (NDA) submission for suzetrigine (VX 548) in moderate-to-severe acute pain

Vertex Pharmaceuticals Incorporated announced important advancements across its suzetrigine pain program, which has the potential to be the first new class of medicine for acute and neuropathic pain in more than two decades. Suzetrigine is an oral selective NaV1.8 pain signal inhibitor (formerly known as VX-548)

1 min

See all news